.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD07_MetforminAndSitagliptin.MetforminAndSitagliptin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD07_MetforminAndSitagliptin.MetforminAndSitagliptin| name: | MetforminAndSitagliptin |
| ATC code: | A10BD07 | route: | oral |
| n-compartments | 1 |
Metformin and sitagliptin is a fixed-dose combination antidiabetic medication used in the treatment of type 2 diabetes mellitus. Metformin is a biguanide antihyperglycemic agent that improves insulin sensitivity and reduces hepatic glucose production, while sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, thereby increasing insulin secretion and decreasing glucagon secretion. The combination is approved and widely used today for glycemic control in adults with type 2 diabetes.
Pharmacokinetic parameters for the combination tablet of metformin (1000 mg) and sitagliptin (100 mg) administered orally to healthy adult volunteers under fasting conditions, as reported in clinical studies.